Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Evaluation of Prescribing Pattern, Therapeutic Adherence and Occurrence of Adverse Drug Reactions in Patients with Type 2 Diabetes Mellitus

Author(s): Sanusi Sani, Md. Sayeed Akhtar*, Prem Kapur, Gunjan Sharma, Fauzia Tabassum, Mohd Faiyaz Khan and Manju Sharma*

Volume 17, Issue 3, 2022

Published on: 17 June, 2022

Page: [177 - 185] Pages: 9

DOI: 10.2174/1574885517666220408110650

Price: $65

Abstract

Background: Persistent hyperglycemia in diabetes mellitus (DM) is considered the leading cause of morbidity and mortality associated with both microvascular and macrovascular complications, having a greater economic impact. This study aimed to assess the impact of socioeconomic status, prescribing patterns, and patient compliance in type 2 diabetes mellitus patients.

Methods: This study was carried out at the Department of Medicine and Diabetic Clinic of Hakeem Abdul Hameed (HAH) Centenary Hospital at Hamdard University, New Delhi, India. We conducted a prospective observational study on prescribing patterns and monitoring adverse drug reactions (ADRs) in patients with type 2 DM (T2DM) under standard care. We enrolled 150 confirmed cases, and data was obtained from pre-validated questionnaires and then coded and analyzed to observe the association between variables.

Results: The glycosylated haemoglobin level in 56% of the cases was between 6.4 to 8.0, and cardiovascular complications were observed as the major comorbidities. 45.33 % of the cases were on mono drug therapy, and metformin (23. 52 %) was the drug of choice, followed by glimepiride (23.52 %). Among the dual drug therapies, sitagliptin with metformin and triple-drug therapy, glimepiride concurrent with metformin and voglibose was the most preferred drug in the treatment of T2DM. Sitagliptin was observed to be a major patient burden (46.213 USD). In only 7.33 % of the cases, we observed definite ADR in T2DM patients. Underprivileged awareness, mainly due to low literacy, was a major concern in the development of new cases of T2DM.

Conclusion: We observed better patient compliance; however, a disease awareness program must be implemented. The use of oral hypoglycaemic drugs is still dominant in clinical practice and cardiovascular disorders as comorbidities emerge as a greater challenge in terms of patient outcome and cost burden.

Keywords: T2DM, socioeconomic study, adverse drug reaction, sitagliptin, cost burden, cardiovascular disorders, prescribing pattern, therapeutic adherence.

« Previous Next »
Graphical Abstract

[1]
Petersmann A, Müller-Wieland D, Müller U A, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2019; 127(S 01): S1-7.
[http://dx.doi.org/10.1055/a-1018-9078]
[2]
Saeedi P, Petersohn I, Salpea P, et al. IDF diabetes atlas committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes Atlasdiabetes Res Clin Pract. 9th Edition. 2019; 157: p. (107843)107843.
[http://dx.doi.org/10.1016/j.diabres.2019.107843]
[3]
Bannier K, Lichtenauer M, Franz M, et al. Impact of diabetes mellitus and its complications: Survival and quality-of-life in critically ill patients. J Diabetes Complications 2015; 29(8): 1130-5.
[http://dx.doi.org/10.1016/j.jdiacomp.2015.08.010] [PMID: 26361811]
[4]
Wilke T, Groth A, Fuchs A, et al. Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients. Diabetes Res Clin Pract 2014; 106(2): 275-85.
[http://dx.doi.org/10.1016/j.diabres.2014.08.002] [PMID: 25176225]
[5]
Grimes RT, Bennett K, Canavan R, Tilson L, Henman MC. The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis. Diabetes Res Clin Pract 2016; 113: 152-9.
[http://dx.doi.org/10.1016/j.diabres.2015.12.020] [PMID: 26810270]
[6]
Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: Within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007; 30(10): 2548-52.
[http://dx.doi.org/10.2337/dc07-0150] [PMID: 17670917]
[7]
Guénette L, Moisan J, Breton M-C, Sirois C, Grégoire J-P. Difficulty adhering to antidiabetic treatment: Factors associated with persistence and compliance. Diabetes Metab 2013; 39(3): 250-7.
[http://dx.doi.org/10.1016/j.diabet.2012.12.005] [PMID: 23523643]
[8]
Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017; 8: 6.
[http://dx.doi.org/10.3389/fendo.2017.00006] [PMID: 28167928]
[9]
World Health Organization. Regional Office for Europe & Dukes, M. N. G. Drug utilization studies: methods and uses. World Health Organization. Available from: https://apps.who.int/iris/handle/ (accessed 2022 -01 -18).
[10]
Hollingworth S, Kairuz T. Measuring medicine use: Applying ATC/DDD methodology to real-world data. Pharmacy (Basel) 2021; 9(1): 60.
[http://dx.doi.org/10.3390/pharmacy9010060] [PMID: 33802774]
[11]
Schatz S, Weber R. Adverse Drug Reactions 2015. Available from: https://www.accp.com/docs/bookstore/psap/2015B2.SampleChapter.pdf (accessed 2022 -01 -18).
[12]
Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J 2014; 22(2): 83-94.
[http://dx.doi.org/10.1016/j.jsps.2013.02.003] [PMID: 24648818]
[13]
Akici A, Oktay S. Rational pharmacotherapy and pharmacovigilance. Curr Drug Saf 2007; 2(1): 65-9.
[http://dx.doi.org/10.2174/157488607779315408] [PMID: 18690951]
[14]
Geier AS, Wellmann I, Wellmann J, et al. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2014; 106(1): 73-80.
[http://dx.doi.org/10.1016/j.diabres.2014.07.014] [PMID: 25139631]
[15]
Hamilton MT, Hamilton DG, Zderic TW. Sedentary behavior as a mediator of type 2 diabetes. Med Sport Sci 2014; 60: 11-26.
[http://dx.doi.org/10.1159/000357332] [PMID: 25226797]
[16]
Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016; 37(3): 278-316.
[http://dx.doi.org/10.1210/er.2015-1137] [PMID: 27159875]
[17]
Kautzky-Willer A, Dorner T, Jensby A, Rieder A. Women show a closer association between educational level and hypertension or diabetes mellitus than males: A secondary analysis from the Austrian HIS. BMC Public Health 2012; 12(1): 392.
[http://dx.doi.org/10.1186/1471-2458-12-392] [PMID: 22646095]
[18]
Fan R, Xu M, Wang J, et al. Sustaining effect of intensive nutritional intervention combined with health education on dietary behavior and plasma glucose in type 2 diabetes mellitus patients. Nutrients 2016; 8(9): 560.
[http://dx.doi.org/10.3390/nu8090560] [PMID: 27649232]
[19]
Berumen J, Orozco L, Betancourt-Cravioto M, et al. Influence of obesity, parental history of diabetes, and genes in type 2 diabetes: A case-control study. Sci Rep 2019; 9(1): 2748.
[http://dx.doi.org/10.1038/s41598-019-39145-x] [PMID: 30808941]
[20]
Senadheera SPAS, Ekanayake S, Wanigatunge C. Dietary habits of type 2 diabetes patients: Variety and frequency of food intake. J Nutr Metab 2016; 2016: 7987395.
[http://dx.doi.org/10.1155/2016/7987395] [PMID: 28127469]
[21]
Gray N, Picone G, Sloan F, Yashkin A. Relation between BMI and diabetes mellitus and its complications among US older adults. South Med J 2015; 108(1): 29-36.
[http://dx.doi.org/10.14423/SMJ.0000000000000214] [PMID: 25580754]
[22]
Chentli F, Azzoug S, Mahgoun S. Diabetes mellitus in elderly. Indian J Endocrinol Metab 2015; 19(6): 744-52.
[http://dx.doi.org/10.4103/2230-8210.167553] [PMID: 26693423]
[23]
Kirkman MS, Briscoe VJ, Clark N, et al. Consensus development conference on diabetes and older adults. Diabetes in older adults: A consensus report. J Am Geriatr Soc 2012; 60(12): 2342-56.
[http://dx.doi.org/10.1111/jgs.12035] [PMID: 23106132]
[24]
Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2007; 298(22): 2654-64.
[http://dx.doi.org/10.1001/jama.298.22.2654] [PMID: 18073361]
[25]
Beulens JWJ, Stolk RP, van der Schouw YT, Grobbee DE, Hendriks HFJ, Bots ML. Alcohol consumption and risk of type 2 diabetes among older women. Diabetes Care 2005; 28(12): 2933-8.
[http://dx.doi.org/10.2337/diacare.28.12.2933] [PMID: 16306557]
[26]
Ceylan-Isik AF, McBride SM, Ren J. Sex difference in alcoholism: Who is at a greater risk for development of alcoholic complication? Life Sci 2010; 87(5-6): 133-8.
[http://dx.doi.org/10.1016/j.lfs.2010.06.002] [PMID: 20598716]
[27]
Welsh KJ, Kirkman MS, Sacks DB. Role of glycated proteins in the diagnosis and management of diabetes: Research gaps and future directions. Diabetes Care 2016; 39(8): 1299-306.
[http://dx.doi.org/10.2337/dc15-2727] [PMID: 27457632]
[28]
Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: Targets and interventions. Diabetes Care 2008; 31(Suppl. 2): S215-21.
[http://dx.doi.org/10.2337/dc08-s257]
[29]
Bahtiyar G, Gutterman D, Lebovitz H. Heart failure: A major cardiovascular complication of diabetes mellitus. Curr Diab Rep 2016; 16(11): 116.
[http://dx.doi.org/10.1007/s11892-016-0809-4] [PMID: 27730517]
[30]
Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: A position statement of the american diabetes association. Diabetes Care 2016; 39(11): 2065-79.
[http://dx.doi.org/10.2337/dc16-1728] [PMID: 27926890]
[31]
Najafipour F, Mobasseri M, Yavari A, et al. Effect of regular exercise training on changes in HbA1c, BMI and VO2max among patients with type 2 diabetes mellitus: An 8-year trial. BMJ Open Diabetes Res Care 2017; 5(1): e000414.
[http://dx.doi.org/10.1136/bmjdrc-2017-000414] [PMID: 29177050]
[32]
Kanatsuka A, Sato Y, Kawai K, et al. Japan Diabetes Clinical Data Management Study Group (JDDM). Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). J Diabetes Investig 2016; 7(3): 386-95.
[http://dx.doi.org/10.1111/jdi.12430] [PMID: 27330726]
[33]
Cavaiola TS, Pettus JH. Management of type 2 diabetes: Selecting amongst available pharmacological agents. In Endotext 2017.
[34]
Tschöpe D, Hanefeld M, Meier JJ, et al. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 2013; 12(1): 62.
[http://dx.doi.org/10.1186/1475-2840-12-62] [PMID: 23574917]
[35]
Vitry AI, Roughead EE, Preiss AK, et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: A cohort study. PLoS One 2010; 5(11): e14024.
[http://dx.doi.org/10.1371/journal.pone.0014024] [PMID: 21103337]
[36]
Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 1996; 13(4): 365-70.
[http://dx.doi.org/10.1002/(SICI)1096-9136(199604)13:4<365:AID-DIA19>3.0.CO;2-M] [PMID: 9162613]
[37]
Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131(3): 182-8.
[http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00004] [PMID: 10428734]
[38]
Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48(12): 2414-21.
[http://dx.doi.org/10.2337/diabetes.48.12.2414] [PMID: 10580431]
[39]
Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. The Troglitazone Insulin Study Group. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 1998; 21(9): 1455-61.
[http://dx.doi.org/10.2337/diacare.21.9.1455] [PMID: 9727891]
[40]
Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2016; 164(11): 740-51.
[http://dx.doi.org/10.7326/M15-2650] [PMID: 27088241]
[41]
World health organization. Diabetes Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes (accessed 2022 -01 -18).
[42]
St Onge EL, Miller S, Clements E. Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus. P&T 2012; 37(12): 699-708.
[PMID: 23319848]
[43]
Shi C, Zhang R, Bai R, et al. Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes. Clinics (São Paulo) 2019; 74: e736.
[http://dx.doi.org/10.6061/clinics/2019/e736] [PMID: 31038562]
[44]
Singh A, Dwivedi S. Study of adverse drug reactions in patients with diabetes attending a tertiary care hospital in New Delhi, India. Indian J Med Res 2017; 145(2): 247-9.
[http://dx.doi.org/10.4103/ijmr.IJMR_109_16] [PMID: 28639602]
[45]
Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. J Pharmacol Toxicol Methods 2016; 81: 323-34.
[http://dx.doi.org/10.1016/j.vascn.2016.04.011] [PMID: 27109493]
[46]
Mendez CE, Umpierrez GE. Pharmacotherapy for hyperglycemia in noncritically Ill hospitalized patients. Diabetes Spectr 2014; 27(3): 180-8.
[http://dx.doi.org/10.2337/diaspect.27.3.180] [PMID: 26246777]
[47]
Zullig LL, Gellad WF, Moaddeb J, et al. Improving diabetes medication adherence: Successful, scalable interventions. Patient Prefer Adherence 2015; 9: 139-49.
[http://dx.doi.org/10.2147/PPA.S69651] [PMID: 25670885]
[48]
Delamater AM. Improving patient adherence. Clin Diabetes 2006; 24(2): 71-7.
[http://dx.doi.org/10.2337/diaclin.24.2.71]
[49]
Khan GH, Aqil M, Pillai KK, et al. Therapeutic adherence: A prospective drug utilization study of oral hypoglycemic in patients with type 2 diabetes mellitus. Asian Pac J Trop Dis 2014; 4: S347-52.
[http://dx.doi.org/10.1016/S2222-1808(14)60469-2]
[50]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461-98.
[http://dx.doi.org/10.1007/s00125-018-4729-5] [PMID: 30288571]
[51]
Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab 2017; 43(6): 501-11.
[http://dx.doi.org/10.1016/j.diabet.2017.06.003] [PMID: 28754263]
[52]
Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm 2013; 19(3): 237-46.
[http://dx.doi.org/10.18553/jmcp.2013.19.3.237] [PMID: 23537458]
[53]
Pawaskar M, Pinar Bilir S, Graber-Naidich A, Gonzalez CD, Rajpathak S, Davies GM. Modeling long-term cost-effectiveness of sitagliptin and SGLT2i combination therapy for the treatment of type 2 diabetes. Diab 2018; 67(Supplement_1): 1247.
[http://dx.doi.org/10.2337/db18-1247-P]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy